Cooley LLP has longstanding experience in advising life sciences companies and investors on venture capital financings, capital markets and licensing. The team was also recently active in Chinese biotech companies’ cross-border M&A, as well as companies looking to list on the US and Hong Kong stock exchanges. In Shanghai, Yiming Liu acts for companies throughout their life cycles, from private financings, strategic M&A and IPO exits, to follow-on offerings and cross-border licensing and collaboration transactions; and Ruomu Li also assists with life sciences-related deals. Working across the firm’s Singapore and Shanghai offices, Patrick Loofbourrow regularly acts for life sciences and healthcare clients on major transactions.
Testimonials
Collated independently by Legal 500 research team.
- ‘Profound industry knowledge and rich practical experience.’
- ‘Able to provide clients with comprehensive legal services, including but not limited to IP protection, financing, M&A, compliance management and dispute resolution.’
Key clients
- Jiangsu Hengrui Pharmaceuticals
- ProfoundBio
Work highlights
- Advised Jiangsu Hengrui Pharmaceuticals on its $6bn licensing of global rights (excluding Greater China) for the development, production and commercialisation of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco.
- Advised ProfoundBio on its $1.8bn sale to Genmab, a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against serious diseases.